Estrogen as neuroprotectant of nigrostriatal dopaminergic system: Laboratory and clinical studies

Endocrine

Volumn 21, Issue 1, 2003, Pages 67-75

  Dluzen, Dean E ^a,c   Horstink, Martin W I M ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Northeast Ohio Medical University   (United States)

Author keywords

Dopamine; Gonadal steroids; Neurodegeneration; Parkinson disease; Progesterone; Testosterone

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 17ALPHA ESTRADIOL; 4 HYDROXYTAMOXIFEN; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; CATECHOLAMINE; CONJUGATED ESTROGEN; DOPAMINE; ESTRADIOL; ESTROGEN; HOMOVANILLIC ACID; LEVODOPA; METHAMPHETAMINE; NEUROLEPTIC AGENT; NEUROTOXIN; PRASTERONE; PROGESTERONE; RALOXIFENE; SEX HORMONE; TAMOXIFEN; TESTOSTERONE;

CATECHOLAMINE BRAIN LEVEL; CELL STRUCTURE; CHOREA; CLINICAL FEATURE; CLINICAL TRIAL; CORPUS STRIATUM; DAILY LIFE ACTIVITY; DENDRITIC CELL; DEPLETION; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; DYSKINESIA; ENZYME ACTIVITY; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; ESTRUS CYCLE; EXTRAPYRAMIDAL SYMPTOM; GENETIC SUSCEPTIBILITY; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPOTHALAMUS; LABORATORY TEST; MENSTRUAL CYCLE; MOTOR ACTIVITY; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ORCHIECTOMY; OVARIECTOMY; PARKINSON DISEASE; PARKINSONISM; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SENSORIMOTOR FUNCTION; SEX DIFFERENCE; STEREOTYPY; SUBSTANTIA NIGRA; TARGET ORGAN;

EID: 0038620461     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1385/ENDO:21:1:67     Document Type: Review

References (104)

1. Lichtensteiger, W. (1969). J. Pharmacol. Exp. Ther. 165, 204-215.
2. Greengrass, P. M. and Tonge, S. R. (1971). J. Pharm. Pharmacol. 23, 897,898.
3. Jori, A. and Cecchetti, G. (1973). J. Endocr. 58, 341, 342.
4. Holzbauer, M. and Youdim, M. B. H. (1973). Br. J. Pharmacol. 48, 600-608.
5. Jori, A., Colturani, F., Dolfini, E., and Rutczynski, M. (1976). Neuroendocrinology 21, 262-266.
6. Crowley, W. R., O'Donohue, T. L., and Jacobowitz, D. M. (1978). Brain Res. 147, 315-326.
7. Fernandez-Ruiz, J. J., Hernandez, M. L., de Miguel, R., and Ramos, J. A. (1991). J. Neural Transm. (Gen. Sect.) 85, 223-229.
8. Becker, J. B. and Ramirez, V. D. (1981). Brain Res. 204, 361-372.
9. Becker, J. B. and Cha, J.-H. (1989). Behav. Brain Res. 35, 117-125.
10. Becker, J. B. and Xiao, L. (1994). Neurosci. Lett. 180, 155-158.
11. Dluzen, D. E. and Ramirez, V. D. (1985). Neuroendocrinology 41, 97-100.
12. Dluzen, D. E. and Ramirez, V. D. (1990). Brain Res. 536, 163-168.
13. Levesque, D., Gagnon, S., and Di Paolo, T. (1989). Brain Res. Bull. 24, 281-284.
14. Di Paolo, T., Falardeau, P., and Morissette, M. (1988). Life Sci. 43, 665-672.
15. Davis, C. F., Davis, B. F., and Halaris, A. E. (1977). Life Sci. 20, 1319-1332.
16. Morissette, M. and Di Paolo, T. (1993). Neuroendocrinology 58, 16-22.
17. Morissette, M., Garcia-Segura, L.-M., Belanger, A., and Di Paolo, T. (1992). Neuroscience 49, 893-902.
18. Becker, J. B., Robinson, T. E., and Lorenz, K. A. (1982). Eur. J. Pharmacol. 80, 65-72.
19. Becker, J. B., Snyder, P. J., Miller, M. M., Westgate, S. A., and Jenuwine, M. J. (1987). Pharmacol. Biochem. Behav. 27, 53-59.
20. Diaz-Veliz, G., Benavides, M. S., Burton, S., Dussaubat, N., and Mora, S. (1999). Pharmacol. Biochem. Behav. 62, 21-29.
21. Gordon, J. H. and Shellenberger, M. K. (1974). Neuropharmacology 13, 129-137.
22. Crowley, W. R., O'Donohue, T. L., and Jacobowitz, D. M. (1978). Acta Endocrinol. 89, 20-28.
23. Becker, J. B. (1999). Pharmacol. Biochem. Behav. 64, 803-812.
24. Gratton, L. (1960). Union Med. Can. 89, 679-694.
25. Crane, G. E. (1968). Am. J. Psychiatry 124(Suppl.), 40-48.
26. Bedard, P., Langelier, P., and Villeneuve, A. (1977). Lancet 2, 1367, 1368.
27. Nausieda, P. A., Koller, W. C., Weiner, W. J., and Klawans, H. L. (1979). Neurology 29, 1605-1609.
28. Lal, S. and Sourkes, T. L. (1972). Arch. Int. Pharmacodyn. 199, 289-301.
29. Nausieda, P. A., Koller, W. C., Weiner, W. J., and Klawans, H. L. (1979). Life Sci. 25, 521-526.
30. Van Hartesveldt, C. and Joyce, J. N. (1986). Neurosci. Biobehav. Rev. 10, 1-14.
31. Di Paolo, T. (1994). Rev. Neurosci. 5, 27-42.
32. Ramirez, V. D., Kim, K., and Dluzen, D. E. (1985). Recent Prog. Horm. Res. 41, 421-472.
33. Menniti, F. S. and Baum, M. J. (1981). Brain Res. 216, 89-107.
34. Savageau, M. M. and Beatty, W. W. (1981). Pharmacol. Biochem. Behav. 14, 17-22.
35. Beatty, W. W., Dodge, A. M., and Traylor, K. L. (1982). Pharmacol. Biochem. Behav. 16, 565-568.
36. Dluzen, D. E. and Ramirez, V. D. (1989). J. Neuroendocrinol. 1, 285-290.
37. Brooks, W. J., Jarvis, M. F., and Wagner, G. C. (1989). Res. Commun. Subst. Abuse 10, 181-184.
38. Freyaldenhoven, T. E., Cadet, J. L., and Ali, S. F. (1996). Brain Res. 735, 232-238.
39. Ali, S. F. and Freyaldenhoven, T. (1999). In: Chemicals and neurodegenerative disease. Bondy, S. C. (ed.). Prominent Press: Scottsdale, AZ.
40. Miller, D. B., Ali, S. F., O'Callaghan, J. P., and Laws, S. C. (1998). Ann. NY Acad. Sci. 844, 153-165.
41. Wagner, G. C., Tekirian, T. L., and Cheo, C. T. (1993). J. Neural Transm. (Gen. Sect.) 93, 67-70.
42. Yu, Y.-L. and Wagner, G. C. (1994). J. Neural Transm. (P-D Sect.) 8, 215-221.
43. Yu, L. and Liao, P.-C. (2000). J. Neural Transm. 107, 419-427.
44. Heller, A., Bubula, N., Lew, R., Heller, B., and Won, L. (2001). J. Pharmacol. Exp. Thera. 298, 769-779.
45. Gomez-Mancilla, B. and Bedard, P. (1992). Neurosci. Lett. 135, 129-132.
46. Dluzen, D. E., McDermott, J. L., and Liu, B. (1996). J. Neurochem. 66, 658-666.
47. Dluzen, D. E., McDermott, J. L., and Liu, B. (1996). Neurotoxicol. Teratol. 18, 603-606.
48. Dluzen, D. E. (1997). Brain Res. 767, 340-344.
49. Gao, X. and Dluzen, D. E. (2001). Neuroscience 103, 385-394.
50. Dluzen, D. E. and McDermott, J. L. (2000). Ann. NY Acad. Sci. 914, 112-126.
51. Dluzen, D. E. and McDermott, J. L. (2002). Ann. NY Acad. Sci. 965, 136-156.
52. Grandbois, M., Morissette, M., Callier, M., and Di Paolo, T. (2000). Neuroreport 11, 343-346.
53. Dluzen, D. E., McDermott, J. L., and Anderson, L. I. (2003). Neurotoxicol. Res. 3, 291-300.
54. Gajjar, T. M., Anderson, L. I., and Dluzen, D. E. (2003). J. Neural Transm., in press.
55. Yu, L., Kuo, Y., Cherng, C. G., Chen, H.-H., and Hsu, C.-H. (2002). Neuroendocrinology 75, 282-287.
56. Anderson, L. I., Leipheimer, R. E., and Dluzen, D. E. (2002). Soc. Neurosci. Abstr., #810.10, 32nd Ann. Mtg.
57. Dluzen, D. E., McDermott, J. L., and Anderson, L. I. (2001). J. Neuroendocrinol. 13, 618-624.
58. Yu, L. and Liao, P.-C. (2000). J. Neural Transm. 107, 1139-1147.
59. Tomas-Camardiel, M., Sanchez-Hidalgo, M. C., Sanchez Del Pino, M. J., Navarro, A., Machado, A., and Cano, J. (2002). Neuroscience 109, 569-584.
60. Gao, X. and Dluzen, D. E. (2001). Brain Res. 892, 63-69.
61. Dluzen, D. E., Disshon, K. A., and McDermott, J. L. (1998). In: Advances in neurodegenerative disorders - vol. 1: Parkinson's disease. Marwah, J. E. and Teitelbaum, H. (eds.). Prominent Press: Scottsdale, AZ.
62. Dluzen, D. E. (2000). J. Neurocytol. 29, 387-399.
63. Dluzen, D. E. and McDermott, J. L. (2000). J. Gender Spec. Diff. 3, 36-42.
64. Dluzen, D. E., Jain, R., and Liu, B. (1994). J. Neurochem. 62, 94-101.
65. Grandbois, M., Tanguay, B., and Di Paolo, T. (1999). Soc. Neurosci. Abstr. 25, 1595.
66. Dluzen, D. E. (1996). Brain Res. 715, 113-118.
67. de la Fuente-Fernandez, R. and Stoessl, A. J. (2002). TINS 25, 302-306.
68. Quinn, N. P. and Marsden, C. D. (1986). Mov. Disord. 1, 85-87.
69. Horstink, M. W. I. M., Strijks, E., and Dluzen, D. E. (2003). Adv. Neurol. 91, 107-114.
70. Kompoliti K., Comella, C. L., Jaglin, J. A., Leurgans, S., Raman, R., and Goetz, C. G. (2000). Neurology 55, 1572-1575.
71. Zhang, Z. and Roman, G. C. (1993). Neuroepidemiology 12, 195-208.
72. Tanner, C. M. and Goldman, S. M. (1996). Neurol. Clin. 14, 317-335.
73. Bower, J. H., Maraganore, D. M., McDonnell, S. K., and Rocca, W. A. (1999). Neurology 52, 1214-1220.
74. Claveria, L. E., Duarte, J., Sevillano, M. D., et al. (2002). Mov. Disord. 17, 242-249.
75. Baldereschi, M., Di Carlo, A., Rocca, W. A., et al. (2000). Neurology 55, 1358-1363.
76. Kuopio, A. M., Marttila, R. J., Helenius, H., and Rinne, U. K. (1999). Neurology 52, 302-308.
77. Elbaz, A., Bower, J. H., Maraganore, D. M., et al. (2002). J. Clin. Epidemiol. 55, 25-31.
78. Behari, M., Srivastava, A. K., Das, R. R., and Pandey, R. M. (2001). Neurol. Sci. 190, 49-55.
79. Swerdlow, R. H., Parker, W. D., Currie, L. J., et al. (2001). Parkinsonism Relat. Disord. 7, 129-133.
80. Shibayama, H., Sato, S., Sakata, S., et al. (2001). Parkinsonism Relat. Disord. 7(Suppl.), s101.
81. Lyons, K. E., Hubble, J. P., Troster, A. L., Pahwa, R., and Koller, W. C. (1998). Clin. Neuropharmacol. 21, 118-121.
82. Tison, F., Dartigues, J. F., Dubes, L., Zuber, M., Alperovitch, A., and Henry, P. (1994). Acta Neurol. Scand. 90, 111-115.
83. de Rijk, M. C., Breteler, M. M., Graveland, G. A., et al. (1995). Neurology 45, 2143-2146.
84. de Rijk, M. C., Launer, L. J., Berger, K., et al. (2000). Neurology 54(Suppl. 5), S21-S23.
85. Horstink, M. W. and Bloem, B. R. (2002). J. Neurol. Neurosurg. Psychiatry 72, 276-277.
86. Lucking, C. B., Durr, A., Bonifati, V., et al. (2000). N. Engl. J. Med. 342, 1560-1567.
87. Nausieda, P. A., Bieliauskas, L. A., Bacon, L. D., Hagerty, M., Koller, W. C., and Glantz, R. N. (1983). Neurology 33, 750-754.
88. Schipper, H. M. (1986). Neurol. Clin. 4, 721-751.
89. Leys, D., Destee, A., Petit, H., and Warot, P. (1987). J. Neurol. 235, 46-48.
90. Cardoso, F. (2002). Arch. Neurol. 59, 868-870.
91. Pelletier, J., Cabanot, C., Levrier, O., Thuillier, J. N., and Cherif, A. A. (1997). Rev. Neurol. 153, 393-397.
92. Omdal, R. and Roalso, S. (1992). Acta Neurol. Scand. 86, 219, 220.
93. Mathur, A. K. and Gatter, R. A. (1988). J. Rheumatol. 15, 1042, 1043.
94. Iskander, M. K. and Khan, M. (1989). J. Rheumatol. 16, 850, 851.
95. Asherson, R. A., Gibson, D. G., Evans, D. W., Baguley, E., and Hughes, G. R. (1988). Ann. Rheum. Dis. 47, 947-953.
96. Sandyk, R. (1989). Int. J. Neurosci. 45, 119-122.
97. Fernandez, H. H. and Lapane, K. L. (2000). Mov. Disord. 15, 1119-1124.
98. Tsang, K. L., Ho, S. L., and Lo, S. K. (2000). Neurology 54, 2292-2298.
99. Blanchet, P. J., Fang, J., Hyland, K., Arnold, L. A., Mouradian, M. M., and Chase, T. N. (1999). Neurology 53, 91-95.
100. Strijks, E., Kremer, J. A., and Horstink, M. W. (1999). Clin. Neuropharmacol. 22, 93-97.
101. Saunders-Pullman, R., Gordon-Elliott, J., Parides, M., Fahn, S., Saunders, H. R., and Bressman, S. (1999). Neurology 52, 1417-1421.
102. Benedetti, M. D., Maraganore, D. M., Bower, J. H., et al. (2001). Mov. Disord. 16, 830-837.
103. Marder, K., Tang, M. X., Alfaro, B., et al. (1998). Neurology 50, 1141-1143.
104. Gonera, E. G., van't Hof, M., Berger, H. J., van Weel, C., and Horstink, M. W. (1997). Mov. Disord. 12, 871-876.